Business, energy, technology, markets and global industry news from Business News Today

Lexeo Therapeutics

PharmaDeviceNews Lexeo Therapeutics
A representative image illustrating Lexeo Therapeutics’ LX2020 gene therapy research after the one-time treatment gained FDA RMAT designation for PKP2-associated arrhythmogenic cardiomyopathy.
Pharma & Biotech

LX2020 gains FDA RMAT status after early PKP2 heart gene therapy data

LX2020 gains FDA RMAT status after early PKP2 heart data. Read what the designation changes and why the evidence remains preliminary.

Read More